The effect of itraconazole pulse therapy on quality of life in Pakistani patients of distolateral subungual onychomycosis
Keywords:
Onychomycosis, quality of life, itraconazoleAbstract
Background Distal and lateral subungual onychomycosis (DLSO) is the most commonclinical type of onychomycosis. The disease causes little physical handicap but it has adevastating effect on quality of life (QOL) particularly in our set up.Objective The purpose of the study was to assess the effect of itraconazole pulse therapy onquality of life in Pakistani patients with DLSO.Methods Sixty-two patients, 47 males and 15 females suffering from DLSO, age range 19 to55 years, who were themselves able to understand and fill the questionnaire related withgeneral and disease-specific QOL in English or Urdu version, were enrolled in the study. Thetotal score ranged from 0-60. The higher the score, the greater was the impact on QOL. Thepatients were subjected to itraconazole pulse therapy and each pulse consisted of 200 mgtwice a day for 7 days, followed by a drug-free interval of three weeks. Two pulses weregiven for fingernail onychomycosis and three pulses for toenail infection. The pre- and posttrialdata was analyzed before and after therapy in 46 finger- and 16 toenail cases of DLSO.Results The disease caused psychosocial problems (92%), economic problems in treatment(89.4%), difficulty in cutting nails (62.9%), physical contact problems with hands (60.8%),discomfort in wearing shoes and walking (56.2%), pain (33.8%), disturbance of work withhands (30.4%) and affected performance in sports (22.5%). After itraconazole pulse therapy,these problems decreased to 12.9%, 14.5%, 6.45%, 6.4%, 12.5%, 4.8%, 6.45% and 3.2%,respectively. The mean pretreatment score in patients with finger- and toenail disease was32+3.4 and 29+4.5, respectively. The score dropped to 4.3+5.4 and 4.4+5.6 (P<0.05) afteritraconazole therapy at last follow-up 32 weeks and 48 weeks for finger- and toenail disease,respectively. Fingernail disease has affected QOL more than toenail disease and longerduration of disease, greater involvement of individual nails and greater number of nailsinvolved was also associated with more serious impact on QOL. Females were found to bemore psychologically upset than males.Conclusion Itraconazole pulse therapy significantly improves the QOL in disto-lateralsubungual onychomycosis of both finger- and toenails in our patients.References
Joish VN, Armstrong EP. Which
antifungal agent for
onychomycosis? A
pharmacoeconomic analysis.
Pharmacoeconomics 2001; 19:
-1002.
Andre J, Achten G.
Onychomycosis. Int J Dermatol
; 26: 481-90.
Zaias N. Onychomycosis. Dermatol
Clin 1985; 3: 445-60.
Scher RK. Onychomycosis: A
significant medical disorder. J Am
Acad Dermatol 1996; 35: S2-5.
Barranco V. New approaches to the
diagnosis and management of
onychomycosis. Int J Dermatol
; 33: 292-9.
Richard B, Odom R. New therapies
for onychomycosis. J Am Acad
Dermatol 1996; 35: S26-30.
Doward LC, McKenna SP.
Evolution of quality of life
assessment. In: Rajagopalan R,
Sheretz EF, Anderson TR, eds.
Care Management of Skin
Diseases. New York: Marcell
Dekker 1998: 9-94.
Lubeck DP, Gause D, Schein JR et
al. A health-related quality of life
measure for use in patients with
onychomycosis: A validation study.
Qual Life Res 1999; 8: 121-9.
Lubeck DP, Patrick DL, McNulty P
et al. Quality of life of persons with
onychomycosis. Qual Life Res
; 2: 341-8.
Shaw JW, Joish VN, Coons SJ.
Onychomycosis: health-related
quality of life considerations.
Pharmacoeconomics 2002; 20: 23-
Elewski BE. Onychomycosis:
Treatment, quality of life and economic issues. Am J Clin
Dermatol 2000; 1: 19-26.
Millikan LE, Powell DW, Drake
LA. Quality of life for patients with
onychomycosis. Int J Dermatol
; 38 (Suppl. 2): 13-6.
Lubeck DP. Measuring healthrelated
quality of life in
onychomycosis. J Am Acad
Dermatol 1998; 38: S64-68.
Turner RR, Testa MA. Measuring
the impact of onychomycosis on
patient quality of life. Qual Life Res
; 9: 39-53.
Stier DM, Gause D, Joseph WS et
al. Patients satisfaction with oral
versus nonoral therapeutic
approaches in onychomycosis. J
Am Podiatr Med Assoc 2001; 91:
-7.
Scher RK. Onychomycosis is more
than a cosmetic problem. Br J
Dermatol 1994; 130 (Suppl. 43):
Drake LA, Scher RK, Smith EB et
al. Effect of onychomycosis on
quality of life. J Am Acad Dermatol
; 38: 702-4.